In this study, we assess the possibility that an ongoing EAP with tofersen, carried out in Italian centers on ALS patients carrying the SOD1 mutation, could alter the concentration of selenium species in the CNS. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.